Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Pete Bantock, Julie Khani


Accelerate Diagnostics this week appointed Pete Bantock as its new chief commercial officer. Recently, Bantock was senior VP and general manager of Ventana Medical Systems, in charge of commercial operations in North America.

Before that, Bantock was general manager of Ventana's Spring Bioscience division, and held various positions at the company, including director of marketing and head of corporate accounts. Prior to working at Ventana, Bantock was manager of South African commercial operations within Abbott Labs' diagnostics division.

The American Clinical Laboratory Association has named Julie Khani to be its senior VP, a new position at the organization. Khani will oversee advocacy and policy operations, and will run a team of three vice presidents.

She recently was vice president of public policy at the National Association of Chain Drug Stores, and before that she was the association's director of federal and legislative affairs. Prior to her 11 years at NACDS, Khani was a legislative manager at Ford Motor Company.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.